Figures & data
Figure 1. Schematic representation of multicore magnetic nanoparticles with their polymeric multifunctional coating.
![Figure 1. Schematic representation of multicore magnetic nanoparticles with their polymeric multifunctional coating.](/cms/asset/890a6641-1215-4b4f-bb99-125995f7285c/ifso_a_12364148_f0001.jpg)
Figure 2. Bioferrofluids characterization.
(A) TEM images of maghemite MNPs in the bioferrofluid; (B) size distribution of spherical maghemite MNPs; (C) DLS size distribution of hydrodynamic size in the bioferrofluids sample.
DLS: Dynamic light scattering; MNPs: Magnetic nanoparticles; TEM: Transmission electron microscopy.
![Figure 2. Bioferrofluids characterization.(A) TEM images of maghemite MNPs in the bioferrofluid; (B) size distribution of spherical maghemite MNPs; (C) DLS size distribution of hydrodynamic size in the bioferrofluids sample.DLS: Dynamic light scattering; MNPs: Magnetic nanoparticles; TEM: Transmission electron microscopy.](/cms/asset/25dfd563-768c-44f2-958d-f844fe8bd5b2/ifso_a_12364148_f0002.jpg)
Figure 3. In vitro relaxation measurement.
Comparative analysis of the transverse relaxation rates (1/T2, s-1) (A) and longitudinal relaxation rates (1/T1, s-1) (B) of bioferrofluids and Endorem® as a function of iron concentration (mM). r2 and r1 were calculated from the slopes of each plot.
![Figure 3. In vitro relaxation measurement.Comparative analysis of the transverse relaxation rates (1/T2, s-1) (A) and longitudinal relaxation rates (1/T1, s-1) (B) of bioferrofluids and Endorem® as a function of iron concentration (mM). r2 and r1 were calculated from the slopes of each plot.](/cms/asset/26cc99f1-cd5f-4447-8b36-5b3dc5a37d22/ifso_a_12364148_f0003.jpg)
Figure 4. A dynamic first-passage bolus tracking curve for both Endorem® and bioferrofluids during an acquisition time of 60 s.
![Figure 4. A dynamic first-passage bolus tracking curve for both Endorem® and bioferrofluids during an acquisition time of 60 s.](/cms/asset/bc0c5785-0895-4a9c-ab49-e41fd8aa8504/ifso_a_12364148_f0004.jpg)
Figure 5. In vivo perfusion MRI.
T2*-weighted images for a mouse brain vasculature before (A, E), 5 min (B, F) and 2 h (C, G) after injection of Endorem® (upper panel) and bioferrofluids (lower panel). rCBV maps for Endorem and bioferrofluids are shown in (D) and (H), respectively.
rCBV: Regional cerebral blood volume
![Figure 5. In vivo perfusion MRI.T2*-weighted images for a mouse brain vasculature before (A, E), 5 min (B, F) and 2 h (C, G) after injection of Endorem® (upper panel) and bioferrofluids (lower panel). rCBV maps for Endorem and bioferrofluids are shown in (D) and (H), respectively.rCBV: Regional cerebral blood volume](/cms/asset/8041d7ad-5748-4ba2-a5e4-458aa86cb37b/ifso_a_12364148_f0005.jpg)
Figure 6. Liver MRI study.
Transverse relaxation time values (A) and signal intensity ratio values (B) of bioferrofluids and Endorem® in liver during 2 h after contrast agent injection. Data are presented as (mean ± SEM).
*Marks significant differences between Endorem and bioferrofluids, according to Mann–Whitney test, n = 10.
![Figure 6. Liver MRI study.Transverse relaxation time values (A) and signal intensity ratio values (B) of bioferrofluids and Endorem® in liver during 2 h after contrast agent injection. Data are presented as (mean ± SEM).*Marks significant differences between Endorem and bioferrofluids, according to Mann–Whitney test, n = 10.](/cms/asset/472660f3-9855-4902-ba8c-731ade69c095/ifso_a_12364148_f0006.jpg)
Figure 7. Transverse relaxation time values of bioferrofluids and Endorem® in liver during 60 days after contrast agent injection.
Data are presented as (mean ± SEM).
*Marks significant differences between Endorem and bioferrofluids, according to Mann–Whitney test, (until 15 days: n = 10; at 30 days: n = 8; and at 60 days: n = 4).
![Figure 7. Transverse relaxation time values of bioferrofluids and Endorem® in liver during 60 days after contrast agent injection.Data are presented as (mean ± SEM).*Marks significant differences between Endorem and bioferrofluids, according to Mann–Whitney test, (until 15 days: n = 10; at 30 days: n = 8; and at 60 days: n = 4).](/cms/asset/8ae136dd-210f-4beb-aafa-796272b4fbe8/ifso_a_12364148_f0007.jpg)
Figure 8. Qualitative iron detection.
Prussian blue assay in mouse liver of non-injected mouse (A) and after 2 h (B, C), 1 day (D, E), 7 days (F, G), 15 days (H, I), 30 days (J, K) and 60 days (L, M) of Endorem® (left panel) and bioferrofluids (right panel) injection. Black arrows are pointing ferric ions which appear as blue colored dots. Scale bar 50 μm.
![Figure 8. Qualitative iron detection.Prussian blue assay in mouse liver of non-injected mouse (A) and after 2 h (B, C), 1 day (D, E), 7 days (F, G), 15 days (H, I), 30 days (J, K) and 60 days (L, M) of Endorem® (left panel) and bioferrofluids (right panel) injection. Black arrows are pointing ferric ions which appear as blue colored dots. Scale bar 50 μm.](/cms/asset/14b2fade-9cb3-4bad-a06d-1a481ae57338/ifso_a_12364148_f0008.jpg)
Table 1. A perspective idea about ferric ion concentration in liver of mice after contrast agent injection using Prussian blue assay.